Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combating infectious diseases through multivalent design.

Erkang Fan1, Ethan A Merritt

  • 1Biomolecular Structure Center, Departments of Biochemistry and Biological Structure, Box 357742, University of Washington, Seattle, WA 98195, USA. erkang@u.washington.edu

Current Drug Targets. Infectious Disorders
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effective Treatment using Bumped Kinase Inhibitor 1708 in a Calf Clinical Model of Cryptosporidiosis.

The Journal of infectious diseases·2026
Same author

<i>In vitro</i> activity of MRS-2541, a novel MetRS inhibitor, against a selection of resistant gram-positive organisms associated with serious hospital infections.

Microbiology spectrum·2026
Same author

CSN5i-3 is an orthosteric molecular glue inhibitor of COP9 signalosome.

Nature·2026
Same author

Orthosteric Molecular Glue Inhibits COP9 Signalosome with Substrate-Dependent Potency.

bioRxiv : the preprint server for biology·2025
Same author

Anti-Cryptosporidium efficacy of BKI-1708, an inhibitor of Cryptosporidium calcium-dependent protein kinase 1.

PLoS neglected tropical diseases·2025
Same author

Bumped Kinase Inhibitors Inhibit both <i>Toxoplasma gondii</i> MAPKL1 and CDPK1.

ACS infectious diseases·2025
Same journal

Discoveries of Tat-TAR interaction inhibitors for HIV-1.

Current drug targets. Infectious disorders·2006
Same journal

Chemosensitizers in drug transport mechanisms involved in protozoan resistance.

Current drug targets. Infectious disorders·2006
Same journal

Neuraminidase inhibitors as antiviral agents.

Current drug targets. Infectious disorders·2006
Same journal

Developments in antiviral drug design, discovery and development in 2004.

Current drug targets. Infectious disorders·2006
Same journal

Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Current drug targets. Infectious disorders·2005
Same journal

The molecular basis for the mode of action of bicyclomycin.

Current drug targets. Infectious disorders·2005
See all related articles

Designing multivalent ligands can mimic, inhibit, or disrupt biological interactions. This review focuses on structure-based design strategies for targeting multimeric bacterial toxins using chemical scaffolds.

Area of Science:

  • Biochemistry and Molecular Biology
  • Chemical Biology
  • Structural Biology

Background:

  • Biological interactions often involve multivalent binding, where multiple identical ligand-receptor pairs link two entities.
  • Examples include cell adhesion, protein complex assembly, and bacterial toxin binding.
  • Multivalent interactions can be modulated by designing specific multivalent ligands.

Purpose of the Study:

  • To review recent advancements in multivalent ligand design.
  • To highlight the application of structure-based design principles.
  • To focus on targeting multimeric bacterial toxins.

Main Methods:

  • Review of recent scientific literature on multivalent ligand design.
  • Analysis of various chemical scaffolds used for ligand construction.

Related Experiment Videos

  • Emphasis on structure-based approaches for targeting multimeric proteins.

    • Main Results:

    • Multivalent ligand design offers effective strategies for modulating biological interactions.
    • Structure-based design is a powerful tool for creating targeted multivalent ligands.
    • Successful examples exist for inhibiting multimeric bacterial toxins.

    Conclusions:

    • Multivalent ligand design is a versatile approach in chemical biology.
    • Structure-based design significantly enhances the specificity and efficacy of multivalent ligands.
    • This strategy holds promise for developing novel therapeutics against bacterial toxins.